Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of ...

The people you spend the most time with outside your home might be playing a role in the composition of the microbes residing ...

Trinity researchers have received awards for 6 projects out of a total 13 projects in the most recent call, and €5.3 million out of a €12.5 million investment from the Health Research Board (HRB) ...

GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...

PBC treatments are available, even after the setback to Intercept Pharmaceuticals’ Ocaliva, but they are unable to reduce ...

GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...

PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...